1naresh
Array ( [urn:ac.highwire.org:guest:identity] => Array ( [runtime-id] => urn:ac.highwire.org:guest:identity [type] => guest [service-id] => ajnr-ac.highwire.org [access-type] => Controlled [privilege] => Array ( [urn:ac.highwire.org:guest:privilege] => Array ( [runtime-id] => urn:ac.highwire.org:guest:privilege [type] => privilege-set [privilege-set] => GUEST ) ) [credentials] => Array ( [method] => guest ) ) ) 1nareshArray ( [urn:ac.highwire.org:guest:identity] => Array ( [runtime-id] => urn:ac.highwire.org:guest:identity [type] => guest [service-id] => ajnr-ac.highwire.org [access-type] => Controlled [privilege] => Array ( [urn:ac.highwire.org:guest:privilege] => Array ( [runtime-id] => urn:ac.highwire.org:guest:privilege [type] => privilege-set [privilege-set] => GUEST ) ) [credentials] => Array ( [method] => guest ) ) )Table 1:Demographic data and clinical scores of subject population
Group (No.) Sex (M/F) Age (yr) Disease Duration (yr) HY HY UPDRS UPDRS MMSE Mean (SD) Mean (SD) (ON) (OFF) (ON) (OFF) (ON) PD (12) 5/7 62.1 (12.7) 5.8 (4.5) 1.8 (0.4)* 1.9 (0.6) 43 (13.8)a 53.3 (22.1) 28.2 Controls (13) 8/5 58.0 (7.3) N/A N/A N/A N/A N/A 28.8
Note:—NA indicates data not available; M, male; F, female; HY, Hoehn and Yahr clinical staging; UPDRS, Unified Parkinson Disease Rating Scale; MMSE, Mini-Mental State Examination; ON, taking medication as normal; OFF, cessation of medication.
* Levodopa equivalent dosage = 585.2 ± 509.8 mg.